Milestone Scientific, Inc. MLSS
- Market cap
- $37.2M
- P/E
- 0.0×
Follow MLSS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.15 | 0.91 | 0.26 | 0.29 | 0.85 | 1.47 | 0.41 | 0.46 | 0.52 | 0.23 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 3.20 | 1.80 | 1.25 | 1.68 | 3.05 | 4.85 | 2.20 | 1.35 | 1.10 | 1.39 |
High Price
|
|||
| 17 | 14 | 16 | 16 | 19 | 26 | 20 | 17 | 17 | 15 |
Employees
|
|||
| 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| 10 | 11 | 10 | 8 | 5 | 10 | 9 | 10 | 9 | 9 |
Revenue
|
|||
| 60.17% | 61.78% | 46.05% | 68.28% | 66.60% | 61.25% | 55.65% | 69.12% | 74.56% | 71.40% |
Gross Margin
|
|||
| (7) | (5) | (8) | (8) | (7) | (7) | (9) | (7) | (5) | (6) |
EBT
|
|||
| (62.18%) | (46.36%) | (83.13%) | (91.27%) | (137.41%) | (69.08%) | (99.63%) | (71.04%) | (54.62%) | (63.76%) |
EBT Margin
|
|||
| (7) | (5) | (8) | (8) | (7) | (7) | (9) | (7) | (5) | (6) |
Net Income
|
|||
| 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| 0.39 | 0.35 | 0.27 | 0.18 | 0.09 | 0.15 | 0.12 | 0.14 | 0.11 | 0.11 |
Revenue/Sh
|
|||
| (0.22) | (0.16) | (0.21) | (0.16) | (0.12) | (0.10) | (0.12) | (0.10) | (0.06) | (0.07) |
Earnings/Sh
|
|||
| (0.20) | (0.04) | (0.05) | (0.04) | (0.11) | (0.06) | (0.09) | (0.07) | (0.04) | (0.04) |
Cash Flow/Sh
|
|||
| 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| (0.20) | (0.04) | (0.05) | (0.04) | (0.11) | (0.06) | (0.09) | (0.07) | (0.04) | (0.04) |
Free CF/Sh
|
|||
| 0.32 | 0.23 | 0.04 | 0.04 | 0.26 | 0.24 | 0.14 | 0.11 | 0.07 | 0.03 |
Book Value/Sh
|
|||
| 27 | 33 | 35 | 46 | 63 | 69 | 71 | 73 | 80 | 82 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 3.34 | 3.22 | 1.21 | 7.59 | 24.59 | 13.76 | 3.93 | 4.89 | 8.88 | 2.47 |
PS Ratio
|
|||
| 4.11 | 4.84 | 7.62 | 39.04 | 8.30 | 8.74 | 3.46 | 5.99 | 13.13 | 7.88 |
PB Ratio
|
|||
| 3.00 | 2.98 | 1.13 | 7.41 | 21.98 | 12.33 | 2.94 | 4.28 | 8.50 | 2.44 |
EV/Sales
|
|||
| (5.79) | (23.56) | (5.94) | (31.24) | (16.59) | (29.92) | (4.15) | (7.61) | (23.44) | (6.99) |
EV/FCF
|
|||
| (5) | (1) | (2) | (2) | (7) | (4) | (6) | (5) | (3) | (3) |
Op' Cash Flow
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capex
|
|||
| (5) | (1) | (2) | (2) | (7) | (4) | (6) | (5) | (3) | (3) |
FCF
|
|||
| 8 | 5 | 1 | 1 | 16 | 16 | 10 | 8 | 6 | 3 |
Working Cap'
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Total Debt
|
|||
| (4) | (3) | (1) | (2) | (14) | (15) | (9) | (6) | (3) | 0 |
Net Debt
|
|||
| 9 | 8 | 2 | 2 | 16 | 16 | 10 | 8 | 6 | 3 |
Sh' Equity
|
|||
| (44.06%) | (34.80%) | (67.47%) | (116.14%) | (56.16%) | (34.63%) | (51.96%) | (55.27%) | (44.53%) | (65.01%) |
ROA
|
|||
| (82.51%) | (67.26%) | (637.05%) | (2,225.62%) | (243.67%) | (313.48%) | (423.81%) | (215.76%) | (160.62%) | (140.88%) |
ROIC
|
|||
| (67.19%) | (64.69%) | (164.62%) | (476.71%) | (82.74%) | (42.19%) | (66.40%) | (76.91%) | (68.09%) | (132.38%) |
ROE
|
|||
Milestone Scientific, Inc. peers in Medical Instruments & Supplies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| HBIO Harvard Bioscience, Inc. | $36.5M | 0.0× | Compare |
| NEPH Nephros Inc. | $45.0M | 27.2× | Compare |
| POCI Precision Optics Corp. | $52.3M | 0.0× | Compare |
| ZTEKF Zentek Ltd. | $62.3M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DXR Daxor Corporation | $66.5M | 5.1× | Compare |
| RVP Retractable Technologies, Inc. | $20.5M | 0.0× | Compare |
| FEMY Femasys Inc. | $20.4M | 0.0× | Compare |
| BNGO Bionano Genomics, Inc. | $19.9M | 0.0× | Compare |
Milestone Scientific, Inc. (MLSS) key facts
- Milestone Scientific, Inc. (MLSS) is a Medical Instruments & Supplies company in the Healthcare sector, listed on NYSE American.
- Milestone Scientific, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, up 3.99% from fiscal 2024.
- Milestone Scientific, Inc. reported a net loss of $5.7 million, or a loss of $0.07 per share, for fiscal 2025.
- As of September 25, 2026, MLSS traded at $0.41, a market capitalization of $37.2 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.1× sales.
- Return on equity was −132.4% and debt-to-equity 0.14.
Milestone Scientific, Inc. (MLSS) Latest News
16 Sep
Milestone Scientific announces Pain and Spine Specialists and Dr. Sudhir Rao as CompuFlo development partner and advisor. Partnership with pain specialists supports CompuFlo development and potential adoption.
26 Aug
Milestone Scientific converted debt from three directors to equity, resulting in a debt-free balance sheet. Debt-free balance sheet improves financial stability and may boost investor sentiment for Milestone Scientific.
14 Aug
Milestone Scientific Inc (MLSS) reported 22% revenue growth in its Q2 2026 earnings call highlights. 22% revenue surge indicates strong operational momentum likely to boost investor sentiment and stock trajectory.
Milestone Scientific, Inc. reported a 25% increase in revenue for the second quarter of 2025, reflecting strong performance and growth in its operations. This growth is attributed to increased demand for its innovative products, which are gaining traction in the market. The company continues to focus on expanding its product offerings and enhancing its market presence. A 25% revenue increase indicates significant growth and potential for future performance improvements.
Milestone Scientific Inc. held its Q2 2026 earnings call covering financial results, operational updates and forward outlook for MLSS. Q2 earnings call supplies financial metrics and guidance that typically produce moderate short-term moves in share price and sentiment.
Milestone Scientific reported financial results for the second quarter of 2026. Quarterly earnings releases typically move stock prices and affect near-term sentiment without altering long-term strategy.
4 Aug
Milestone Scientific partners with Red One Medical to distribute the CompuFlo Epidural System across U.S. federal medical facilities including VA hospitals and military treatment centers. Federal distribution deal expands core product reach into large government healthcare channels and supports revenue growth.
15 Jul
Milestone Scientific launches first phase of AI strategy with pilot debut of Milo, an AI-enabled digital engagement platform, at ASPN 2026. AI platform pilot debut represents major strategic product launch that can shift competitive positioning and investor sentiment for MLSS.
25 Jun
Milestone Scientific adds board members to support its next growth phase. Board expansion aids strategic oversight and growth execution with moderate influence on operations and sentiment.
27 May
Milestone Scientific reports rising clinical adoption and physician acceptance of CompuFlo across epidural, neuromodulation, and interventional pain procedures. Growing CompuFlo adoption signals improving commercial traction that may lift near-term sentiment and procedure volumes without major strategic or regulatory shifts.
14 May
Milestone Scientific Inc. (MLSS) Q1 2026 earnings call highlights strategic growth amid global challenges, emphasizing key financials, product advancements, and market expansion plans. Strategic growth initiatives in Q1 2026 earnings call indicate significant positive shifts in financial performance and competitive positioning.
Milestone Scientific, Inc. (MLSS) reported financial results for the first quarter of 2026. Quarterly financial results disclosure typically drives significant shifts in investor sentiment and stock valuation for MLSS.
Milestone Scientific Inc. released Q1 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Q1 earnings summary affects financial performance and market sentiment moderately without transformative shifts.
7 May
Milestone Scientific expands CompuFlo medical business with new advisor program amid growing national clinical adoption. Advisor program launch and national clinical adoption growth represent major strategic expansion boosting product market penetration and revenue trajectory.
21 Apr
Milestone Scientific Inc. completed a $2.15 million private placement. The $2.15 million private placement provides significant funding to support operations and growth initiatives.
1 Apr
Milestone Scientific Inc (MLSS) Q4 2025 earnings call highlights strategic growth initiatives amid key financial and operational updates. Earnings call highlights strategic growth directly signaling major positive shifts in financial performance and market positioning.
Milestone Scientific Inc. Q4 2025 earnings call summarizes financial results, operational updates, and future guidance for the quarter. Q4 earnings call summary details financial performance and strategic outlook, significantly influencing investor sentiment and stock trajectory.
31 Mar
Milestone Scientific, Inc. (MLSS) reported financial results for the fourth quarter and full year 2025. Quarterly and annual financial results directly influence financial performance and investor sentiment.
23 Feb
Milestone Scientific launches CompuFlo® Advisor Program to accelerate commercial adoption and drive utilization growth in select MAC jurisdictions, planning national expansion. Strategic advisor program targets key jurisdictions to boost CompuFlo adoption and utilization, with national expansion poised to significantly enhance revenue growth and market penetration.
6 Jan
Milestone Scientific, Inc. has launched The Wand® Ambassador Program aimed at enhancing peer engagement and accelerating the adoption of its dental technology. This initiative seeks to leverage the experiences of dental professionals to promote the benefits of The Wand® system, which is designed to improve patient comfort during dental procedures. By fostering a community of ambassadors, Milestone aims to increase awareness and usage of its innovative products in the dental market. The launch of The Wand® Ambassador Program is a significant strategic move that could enhance market penetration and influence investor sentiment.
14 Nov
Milestone Scientific, Inc. reported its Q3 2025 earnings, highlighting strategic expense reductions aimed at improving financial performance. The company is focusing on optimizing operations and enhancing product offerings to drive growth. Management emphasized the importance of maintaining a strong cash position while navigating market challenges. Future initiatives are expected to align with these strategic goals, potentially positioning the company for better performance in the upcoming quarters. Strategic expense reductions and operational optimizations may moderately influence financial performance and market sentiment.
13 Nov
Milestone Scientific, Inc. reported stable revenue and successfully reduced operating expenses by over $500,000 in the third quarter of 2025, indicating improved financial management and operational efficiency. The reduction in operating expenses and stable revenue may moderately influence the company's financial performance and market sentiment.
Milestone Scientific, Inc. has scheduled a conference call to discuss its financial results and business updates for the third quarter of 2025. The call aims to provide insights into the company's performance and future strategies. The scheduled conference call may provide insights that could moderately influence investor sentiment and operational aspects.
14 Oct
Milestone Scientific, Inc. has announced significant operational progress and growth initiatives under its new leadership. The company is focusing on enhancing its product offerings and expanding its market presence, aiming to leverage innovative technologies to drive future growth. Key strategies include improving operational efficiencies and exploring new business opportunities to strengthen its competitive position in the industry. The new leadership's strategic initiatives and focus on innovation are likely to significantly impact the company's future performance and market positioning.
Milestone Scientific, Inc. has announced its commitment to regain compliance with the NYSE American after receiving a notification regarding its non-compliance. The company is taking necessary steps to address the issues raised and aims to meet the exchange's listing standards. Milestone Scientific is focused on ensuring its operations align with regulatory requirements to maintain its listing status. Regaining compliance with NYSE American is crucial for maintaining investor confidence and market presence.
22 Sep
Milestone Scientific, Inc. has appointed Dr. Dawood Sayed to its Board of Directors to enhance its commercial and clinical strategies in pain management. Dr. Sayed brings extensive experience in the medical field, particularly in pain management and anesthesiology, which is expected to support the company's growth and innovation in this area. The appointment of Dr. Sayed is a significant strategic move that could enhance Milestone Scientific's competitive position in the pain management market.
16 Aug
Milestone Scientific, Inc. (MLSS) reported strong revenue growth in Q2 2025, driven by increased demand for its innovative dental and medical technologies. The company highlighted significant advancements in product development and expansion into new markets, which contributed to improved financial performance. Management expressed optimism about future growth prospects and ongoing investments in research and development to enhance product offerings. Strong revenue growth and product advancements indicate significant potential for future performance and market positioning.
6 Aug
Milestone Scientific, Inc. has appointed Jason Papes as Senior Vice President and Global Head of Sales and Marketing. Papes brings over 20 years of experience in the medical device industry, having held leadership roles at various companies. His appointment is expected to enhance Milestone's sales and marketing strategies as the company aims to expand its market presence and drive growth. Papes' extensive experience in the medical device industry may positively influence Milestone's sales and marketing efforts, impacting overall performance.
1 Aug
Milestone Scientific, Inc. has appointed Eric C. Hines as the new Chief Executive Officer, effective immediately. Hines brings over 25 years of experience in the medical device industry, having held various leadership roles. His appointment is expected to drive the company's growth and innovation in its product offerings, particularly in the dental and medical sectors. Hines expressed enthusiasm for leading Milestone Scientific and advancing its mission to enhance patient care through innovative technologies. The appointment of a seasoned CEO with extensive industry experience is likely to significantly influence the company's strategic direction and market performance.
17 Jul
Milestone Scientific, Inc. has begun commercial sales of its CompuFlo® Epidural System at The Painless Center in Tenafly, New Jersey. Led by Dr. Chi-Shin Jason Chiu, the center focuses on enhancing patient safety and comfort through advanced technologies. The CompuFlo system utilizes proprietary DPS Dynamic Pressure Sensing® technology to provide real-time feedback during epidural procedures, improving accuracy and reducing complications. This rollout follows successful deployments at various medical institutions, reflecting Milestone's commitment to expanding its presence in the interventional pain market. The launch of the CompuFlo Epidural System at a reputable medical center signifies a strategic move that could enhance Milestone's market position and investor sentiment.